InsiderTrades

Form 4 for FDMT 4D Molecular Therapeutics, Inc.

Accepted 2026-03-24 00:00:00 ET · period of report 2026-03-20 · accession 0001193125-26-122341 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-03-24 2026-03-20 FDMT Gupta Ashoo VP, Fin, Ctrl S - Sale+OE $8.61 -390 47.1K -0.8% -$3,358
DM 2026-03-24 2026-03-20 FDMT Gupta Ashoo VP, Fin, Ctrl M - OptEx — +1,086 47.1K +2% —
DM 2026-03-24 2026-03-20 FDMT Gupta Ashoo VP, Fin, Ctrl M - OptEx $0.00 -1,086 3,087 -26% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-20 S D 310 $8.61 46,914 D — —
2 Common Common Stock 2026-03-20 M A 865 — 47,224 D — — (F1) Restricted Stock Units convert into common stock on a one-for-one basis.
3 Common Common Stock 2026-03-20 M A 221 — 47,135 D — — (F1) Restricted Stock Units convert into common stock on a one-for-one basis.
4 Common Common Stock 2026-03-20 S D 80 $8.61 47,055 D — —
5 Derivative Restricted Stock Units 2026-03-20 M D 865 $0.00 12,119 D — · — to — 865 Common Stock (F1) Restricted Stock Units convert into common stock on a one-for-one basis. (F3) The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
6 Derivative Restricted Stock Units 2026-03-20 M D 221 $0.00 3,087 D — · — to — 221 Common Stock (F1) Restricted Stock Units convert into common stock on a one-for-one basis. (F4) The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.